This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-26. Anything still debated is marked as such rather than presented as settled.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Drugs are also used to inhibit enzymes needed for the survival of pathogens. For example, bacteria are surrounded by a thick cell wall made of a net-like polymer called peptidoglycan. Many antibiotics such as penicillin and vancomycin inhibit the enzymes that produce and then cross-link the strands of this polymer together. This causes the cell wall to lose strength and the bacteria to burst. In the figure, a molecule of penicillin (shown in a ball-and-stick form) is shown bound to its target, the transpeptidase from the bacteria Streptomyces R61 (the protein is shown as a ribbon diagram). Antibiotic drug design is facilitated when an enzyme that is essential to the pathogen's survival is absent or very different in humans. Humans do not make peptidoglycan, therefore antibiotics that inhibit this process are selectively toxic to bacteria. Selective toxicity is also produced in antibiotics by exploiting differences in the structure of the ribosomes in bacteria, or how they make fatty acids.
As the urban area continued to expand, much of rural Scarborough was converted to suburban housing developments in the last third of the 20th century. At the start of the 21st century, growth occurred along the Highway 401 corridor at the northern end of the Scarborough RT; highrise condominium projects have increased the residential density around Scarborough City Centre. In 1988, there was a reorganization. The board of control was abolished. Alderman was changed to councillor. Six additional metro council positions were created and these were elected separately for the first time. Scarborough's council consisted of a mayor, 14 local councillors and six Metro councillors. In 1998, the municipality of Scarborough was dissolved and the district amalgamated with East York, Etobicoke, North York, York, and the old city of Toronto into the current city of Toronto.
January 23: Law granting an additional benefit to pregnant women already receiving allowances under the law of August 5, 1914. June 18: Law amending the law of April 7, 1915, authorizing the government to revoke naturalization decrees of former nationals of enemy countries: naturalized persons from a country at war with France can be stripped of French nationality, and this loss may extend to the wife and children depending on circumstances. July 27: Law establishing "Wards of the Nation"; women may hold positions in national and departmental offices. August 5: Law concerning breastfeeding in industrial and commercial establishments. October 1: Law on the repression of public drunkenness and regulation of drinking establishments; part of a campaign against clandestine prostitution by both women and men. Additionally, girls under 18 may no longer work in drinking establishments unless they are family members of the owner. 1919
Sources: en.wikipedia.org
==== Wet ==== The irradiated bismuth (or sometimes bismuth trioxide) target is first dissolved in, for example, concentrated nitric or perchloric acid. Following this first step, the acid can be distilled away to leave behind a white residue that contains both bismuth and the desired astatine product. This residue is then dissolved in a concentrated acid, such as hydrochloric acid. Astatine is extracted from this acid using an organic solvent such as dibutyl ether, diisopropyl ether (DIPE), or thiosemicarbazide. Using liquid-liquid extraction, the astatine product can be repeatedly washed with an acid, such as HCl, and extracted into the organic solvent layer. A separation yield of 93% using nitric acid has been reported, falling to 72% by the time purification procedures were completed (distillation of nitric acid, purging residual nitrogen oxides, and redissolving bismuth nitrate to enable liquid–liquid extraction). Wet methods involve "multiple radioactivity handling steps" and have not been considered well suited for isolating larger quantities of astatine. However, wet extraction methods are being examined for use in production of larger quantities of astatine-211, as it is thought that wet extraction methods can provide more consistency. They can enable the production of astatine in a specific oxidation state and may have greater applicability in experimental radiochemistry.
Feminizing hormone therapy is typically used by transgender women, who desire the development of feminine secondary sex characteristics. Individuals who identify as non-binary may also opt-in for feminizing hormone treatment to better align their body with their desired gender expression. Feminizing hormone therapy usually includes medication to suppress testosterone production and induce feminization. Types of medications include estrogens, antiandrogens (testosterone blockers), and progestogens. Most commonly, an estrogen is combined with an antiandrogen to suppress and block testosterone. This allows for demasculinization and promotion of feminization and breast development. Estrogens are administered in various modalities including injection, transdermal patch, and oral tablets. The desired effects of feminizing hormone therapy focus on the development of feminine secondary sex characteristics. These desired effects include: breast tissue development, redistribution of body fat, decreased body hair, reduction of muscle mass, and more. The table below summarizes some of the effects of feminizing hormone therapy in transgender women:
=== Transport === Export of sodium ions from the cell provides the driving force for several secondary active transporters such as membrane transport proteins, which import glucose, amino acids and other nutrients into the cell by use of the sodium ion gradient. Another important task of the Na+-K+ pump is to provide a Na+ gradient that is used by certain carrier processes. In the gut, for example, sodium is transported out of the reabsorbing cell on the blood (interstitial fluid) side via the Na+-K+ pump, whereas, on the reabsorbing (lumenal) side, the Na+-glucose symporter uses the created Na+ gradient as a source of energy to import both Na+ and glucose, which is far more efficient than simple diffusion. Similar processes are located in the renal tubular system.
== Signs and symptoms == Dyspnea (breathlessness) is the most common symptom associated with PAH and also usually the first symptom, with 98% of people experiencing dyspnea at the time of diagnosis. Fatigue, lightheadedness, palpitations, chest pain are also present. Late findings include near-syncope or syncope (fainting). As PAH progresses and chronically elevated pulmonary arterial pressures result in right heart failure; swelling of the legs and other areas of the body (edema), fluid buildup in the abdomen (ascites) develop as late symptoms. Findings on physical exam indicating right heart failure may be present, including a loud P2 heart sound (the sound from the pulmonic valve closing), a heart murmur indicating tricuspid regurgitation or an elevated jugular venous pressure. The WHO introduced a functional classification in PAH which is used to estimate disease severity as well as response to treatment. WHO class 1 is characterized by no limitations with usual physical activity. Class 2 involves discomfort with physical activity and mild limitations. Class 3 disease involves a marked limitation with physical activity and symptoms being present with light activities. Class 4 disease involves severe symptoms with almost any physical activity and symptoms being present at rest.
Sources: en.wikipedia.org
=== Arts critics === Gustav Kobbé (1877), opera scholar and music critic of the New York Herald Clifton Fadiman (1925), book critic for The New Yorker and judge for the Book of the Month Club Edward Downes (1933), music critic, former host on the Metropolitan Opera radio broadcasts, son of music critic Olin Downes Ralph J.
=== Dressings === After a wound is irrigated, debrided, and, if possible, closed, it should be dressed appropriately. The goals of a wound dressing are to act as a barrier to the outside environment, facilitate wound healing, promote hemostasis, and act as a form of mechanical debridement during dressing changes. The ideal wound dressing maintains a moist environment to optimize wound healing but is also capable of absorbing excess fluid as to avoid skin maceration or bacterial growth. Several wound dressing options are available, each tailored to different kinds of wounds:
The dairy industry market size in Haryana is predicted to grow at 15% CAGR from 2021 to 2026, major players being Vita, Amul, Mother Dairy, Kwality, etc. In 2025, Amul's Sabar Dairy Plant at IMT Rohtak was expanded making it India's largest processing plant for curd, buttermilk, and yoghurt catering for the Haryana, Delhi-NCR, and northern India region. In 2025, Haryana was India's third largest producer of milk (122.2 lakh tonnes per year) with highest per capita milk availability in India (1,105 grams per day). Rich in zinc, calcium, proteins, magnesium, and vitamin D and B12, milk can be turned into various products such as liquid milk, ghee, curd, paneer, ice-cream, table butter, skimmed milk powder, frozen/flavoured yoghurt, fresh cream, lassi, butter milk, cheese, flavoured milk, UHT milk, dairy whitener, sweet condensed milk, infant food, and malt-based beverages.
== Constitutional issues == Several of the convention's provisions are prefaced with the words, "Subject to its constitutional principles and the basic concepts of its legal system, each Party shall ..." According to Fazey, "This has been used by the USA not to implement part of article 3 of the 1988 Convention." Similarly, if a national prohibition on drug possession violated a nation's constitution, those provisions would not be binding on that country.
Male progeny prove Flora's unfertilized eggs were haploid (n) and doubled their chromosomes later to become diploid (2n) (by being fertilized by a polar body, or by chromosome duplication without cell division), rather than by her laying diploid eggs by one of the meiosis reduction-divisions in her ovaries failing. When a female Komodo dragon (with ZW sex chromosomes) reproduces in this manner, she provides her progeny with only one chromosome from each of her pairs of chromosomes, including only one of her two sex chromosomes. This single set of chromosomes is duplicated in the egg, which develops parthenogenetically. Eggs receiving a Z chromosome become ZZ (male); those receiving a W chromosome become WW and fail to develop, meaning that only males are produced by parthenogenesis in this species. It has been hypothesised that this reproductive adaptation allows a single female to enter an isolated ecological niche (such as an island) and by parthenogenesis produce male offspring, thereby establishing a sexually reproducing population (via reproduction with her offspring that can result in both male and female young). Despite the advantages of such an adaptation, zoos are cautioned that parthenogenesis may be detrimental to genetic diversity.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.